TITAN BIOTECH LTD.

Titan Biotech Limited announced the outcome of its Board Meeting held on November 05, 2026. The Board of Directors approved the Unaudited Standalone and Consolidated financial results for the quarter and half-year ended September 30, 2026. These results were reviewed by the Audit Committee prior to board approval. The company also provided the Limited Review Report issued by its statutory auditors. The meeting commenced at 3:00 PM and concluded at 3:32 PM. The financial information will be available on the company's website and the BSE website.

Titan Biotech's consolidated revenue rose 40.7% YoY to ₹76.46 Cr (₹54.35 Cr a year ago) and 29.2% QoQ (₹59.17 Cr in Q1 FY27), with consolidated PAT up 61.6% YoY to ₹12.55 Cr (₹7.76 Cr) and 15.6% QoQ (₹10.86 Cr). Consolidated PAT runs ₹1.22 Cr ahead of the standalone ₹11.33 Cr print, the gap being the company's share of profit from associates Peptech Biosciences Limited and Titan Media Limited — standalone and consolidated tell broadly the same operating story, with the associate stake adding roughly 11% to the bottom line. Margins expanded YoY but eased sequentially: OPM (EBITDA/revenue) was 19.63% versus 17.16% a year ago but down from 21.11% in Q1 FY27, while NPM improved to 16.05% from 13.95% YoY but slipped from 17.80% QoQ. Neither period carries exceptional or one-off items (the exceptional-items line is blank throughout), so the YoY margin gain reflects genuine operating leverage on the 40.7% revenue growth rather than a base-effect distortion, while the QoQ give-back points to a cost or mix headwind the filing doesn't break out by segment. No prior management guidance or concall commentary is on record for this company, and no management press release was available for this result, so neither can be checked against the print. A web search turned up no broker previews or consensus estimates for Titan Biotech's Q2 FY27 — the stock appears to carry no formal analyst coverage — so the vs-street read is unknown rather than a beat or miss. The quarter's other corporate actions sit outside the P&L: the company allotted 1.03 Cr bonus shares in a 1:4 ratio (record date October 23, 2026, after this quarter closed) following a ₹40 Lakh increase in authorized share capital approved at the September 29, 2026 AGM. Reported basic EPS rose QoQ (₹3.04 versus ₹2.63 in Q1 FY27, consistent with the profit increase) but fell sharply YoY (₹3.04 versus ₹9.40 a year ago) even though profit grew — a drop inconsistent with the paid-up equity capital of ₹826.37 Lakh shown identically across every column of this statement, including the year-ago quarter. This points to an unreconciled share-count change behind the YoY EPS figure that the filing does not explain; it is flagged for human review rather than folded into the operating verdict, which rests on the clean revenue and profit trends.

Titan Biotech Ltd has announced that its Board of Directors will convene on November 5, 2026, to consider and approve the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The meeting will also address any other business as permitted by the Chairman. Concurrently, the company has closed its trading window for designated persons from October 1, 2026, until 48 hours after the board meeting's outcome is declared, in compliance with SEBI's Insider Trading Regulations.

Titan Biotech Ltd has announced the allotment of 1,03,29,625 fully paid-up bonus equity shares of Rs. 2/- each. This allotment is in the ratio of 1:4, meaning one new share for every four existing shares held by eligible shareholders as of the record date, October 23, 2026. The company's paid-up equity share capital will increase from Rs. 8,26,37,000 to Rs. 10,32,96,250 post-allotment. The Board of Directors approved the allotment on October 26, 2026, following shareholder approval at the AGM on September 29, 2026.

Titan Biotech Ltd has announced October 23, 2026, as the record date to determine shareholder eligibility for a 1:4 bonus share issue. The company received in-principle approval from BSE Limited on October 7, 2026, for the issuance of 1,03,29,625 bonus equity shares of Rs. 2 each. This follows shareholder approval at the 34th Annual General Meeting on September 29, 2026. The deemed date of allotment is October 26, 2026, with the bonus shares expected to be available for trading on October 27, 2026, in compliance with SEBI regulations.

Titan Biotech Limited announced an increase in its authorized share capital from ₹10 Crore to ₹10.40 Crore. This alteration, approved at the 34th Annual General Meeting held on September 29, 2026, involves the creation of 20,00,000 new equity shares of ₹2 each. The company's Memorandum of Association (MOA) has been amended accordingly. The total authorized capital now stands at ₹10,40,00,000 divided into 5,20,00,000 equity shares of ₹2 each. This move is in compliance with SEBI Listing Regulations.

Titan Biotech Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code of conduct. The window will be shut from October 01, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. This measure is to prevent potential insider trading activities around the announcement of financial results. The specific date for the board meeting to approve these results will be communicated later.

Titan Biotech Limited has announced its 34th Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 03:00 P.M. IST. The meeting will be conducted through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) in compliance with current regulations. Shareholders whose email addresses are not registered will receive a letter with a web-link to access the Annual Report and AGM Notice. The Annual Report for FY 2025-26 and the AGM Notice are available on the company's website.

Titan Biotech Ltd has filed its 34th Annual Report for the financial year 2025-26. The report, along with the notice for the 34th Annual General Meeting (AGM), is being disseminated electronically to shareholders. The AGM is scheduled for Tuesday, September 29, 2026, at 3:00 p.m. IST, to be conducted via Video Conferencing (VC) / Other Audio Visual Means (OA VM). The Annual Report details the company's financial and non-financial performance, strategic priorities, and value creation model, adhering to the Integrated Reporting Framework and Indian Accounting Standards. It is available on the company's website.

Titan Biotech Ltd has issued a notice for its 34th Annual General Meeting (AGM) scheduled for Tuesday, September 29, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM), in compliance with SEBI and MCA circulars. The company has also made its Annual Report for the financial year 2025-26 available to shareholders electronically and on its website. The Annual Report provides a comprehensive overview of the company's performance, strategy, governance, and value creation model for the fiscal year.